Hardly an issue of any primary care...

Hardly an issue of any primary care medical journal, including this issue of American Family Physician, can be exhibited without encountering an article upon type 2 diabetes, dyslipidemia, or hypertension. Furthermore, newspapers and television recently made knowns shows are replete with reports about the epidemic of obesity and inferable [i]or[/i] inferrible diabetes in the U.S. population. It is rare to diocese type 2 diabetes, dyslipidemia, obesity, or hypertension in isolation. The evidence advises that these four conditions (and others) at short intervals coexist in what was described by way of Reaven in 1988 as syndrome X now known as the metabolic syndrome (1) An article (2) in JAMA placed the prevalence of metabolic syndrome in the United States at 24 percent--and the prevalence appears to be increasing.

There is general agreement that insulin resistance is the underlying cause of metabolic syndrome Insulin resistance and resulting hyperinsulinemia have been implicated in the disentanglement of glucose intolerance (and progression to emblem 2 diabetes), hypertriglyceridemia, hypertension, polycystic ovary syndrome hypercoagulability, and vascular inflammation, as well as the eventual progression in a continuously ascending gradation of atherosclerotic cardiovascular disease manifested as myocardial infarction, thump and myriad end-organ diseases. by conversion treatment and consequent improvement of insulin resistance have been shown to follow in better outcomes in virtually all of these conditions.

command and medical organizations have focused a great deal of attention in succession the diagnosis and treatment of the various component parts of metabolic syndrome such as pattern 2 diabetes, hypertension, obesity, dyslipidemias, and their associated comorbidities. More not long ago investigators have begun to focus forward understanding the underlying causes of these conditions, and attention is starting to shift toward screening and prevention. Unfortunately, because of the previous lack of pious data, organizations such as the American Diabetes Association (ADA) (3) and the U Preventive Services Task Force (USPSTF) (4) disagree about the appropriateness of screening the general population for diabetes, and about what constitutes a "susceptible" population. The ADA make acceptables screening men and women 45 years and older for impaired fasting grape-sugar or impaired glucose tolerance and considering screening younger patients with an elevated carcass mass index. The USPSTF does not make acceptable routine screening of asymptomatic adults.

The now passing recommendations for the management of hypertension, pattern 2 diabetes, obesity and dyslipidemias aim primarily at screening and treating each point in dispute separately. Beyond lifestyle changes, scarcely any measures have been available for addressing the origin problem--insulin resistance. Recently, however, evidence has started to surface about the usefulness of pharmacologic interventions.

Perhaps the principally significant challenge in the prevention of metabolic syndrome is the lack of a diagnostic proof To diagnose the syndrome, the physician has to rely onward clinical observations and a high index of suspicion. Unfortunately, from the time signs are discovered the damage often has been done.

There also is no simple, clinically applicable standard for insulin resistance. Use of the hyperinsulinemic clamp, a laboratory technique used to quantify insulin resistance, is cumbersome and expensive. Measurement of insulin flushs is not reliable because of poor specificity. one interesting correlations have been ground between insulin resistance and plasma horizontals of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, (5) however clinical applicability remains an issue.

Although we cannot defence for insulin resistance, we have the ability to identify [i]clavis[/i] components of the metabolic syndrome and to provide interventions extended before end-organ damage is evident. Regular screening of lipid flats blood pressure, and blood starch-sugar levels in susceptible patients is tonic to early identification of the syndrome processs for evaluating dyslipidemia and hypertension are readily available to physicians. The evaluation of grape-sugar abnormalities is more challenging. by means of the time hyperglycemia develops, hyperinsulinemia has been at hand and causing damage for years.

In this issue of AFP, Rao and associates (6) quick in emergencies a reasonable, practical clinical approach to identifying patients before they expand overt diabetes and its complications. Data from the Diabetes Prevention consideration show that lifestyle modifications and pharmacologic therapy can stop the development of type 2 diabetes. (7) When the same fourth of the general U population is at risk for developing a preventable condition, a more aggressive approach is warranted.

The part of the family physician is clear. Patients at risk for exemplar 2 diabetes will not ready to an endocrinologist, a cardiologist, or any other subspecialist until symptoms appear. Therefore, the family physician must be vigilant and intervene early enough to make a difference.